Study Evaluating DVS-233 SR for Treatment of Vasomotor Symptoms Associated With Menopause
NCT ID: NCT00195546
Last Updated: 2007-06-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE3
465 participants
INTERVENTIONAL
2005-04-30
2006-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
SINGLE_GROUP
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DVS-233
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Minimum of 7 moderate to severe hot flashes per day or 50 per week recorded for 7 consecutive days
* Body Mass Index less than or equal to 34 kg/m2 using the nomograph for BMI.
Exclusion Criteria
* Active or recent arterial thromboembolic disease; History of venous thromboembolism
* History of cerebrovascular accident, stroke, or transient ischemic attack -
* Presence of major depressive disorder, bipolar disorder, psychotic disorder, or generalized anxiety disorder requiring therapy
* Persistent elevated blood pressure
40 Years
65 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wyeth is now a wholly owned subsidiary of Pfizer
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Monitor
Role: STUDY_DIRECTOR
Wyeth is now a wholly owned subsidiary of Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Leuven, , Belgium
Zadar, , Croatia
Zagreb, , Croatia
Olomuc, , Czechia
Ostrava, , Czechia
Přerov, , Czechia
Kuopio, , Finland
Kuopio, , Finland
Oulu, , Finland
Évry, , France
Paris, , France
Paris, , France
Debrecen, , Hungary
Tatabánya, , Hungary
Del. Cuauhtemoc, , Mexico
Lomas Virrteyes, , Mexico
's-Hertogenbosch, , Netherlands
Hengelo, , Netherlands
Nijmegen, , Netherlands
Katowice, , Poland
Poznan, , Poland
Warsaw, , Poland
Wroclaw, , Poland
Bucharest, , Romania
Bucharest, , Romania
Bucharest, , Romania
Bucharest, , Romania
Bloemfontein, , South Africa
Centurion, , South Africa
Parow, , South Africa
Madrid, , Spain
Linköping, , Sweden
Stockholm, , Sweden
Uppsala, , Sweden
Donetsk, , Ukraine
Kyiv, , Ukraine
Kyiv, , Ukraine
Fowey, , United Kingdom
Leicester, , United Kingdom
London, , United Kingdom
Plymouth, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
3151A2-321
Identifier Type: -
Identifier Source: org_study_id